Wall Street Zen Upgrades Metsera (NASDAQ:MTSR) to Hold

Metsera (NASDAQ:MTSR) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Wednesday.

MTSR has been the subject of several other reports. Wells Fargo & Company downgraded Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 target price for the company. in a research note on Tuesday. Leerink Partners reissued a “market perform” rating and issued a $57.00 price objective (down from $77.00) on shares of Metsera in a research note on Wednesday, September 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Leerink Partnrs downgraded Metsera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 24th. Finally, Bank of America increased their price objective on Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Metsera has a consensus rating of “Moderate Buy” and a consensus price target of $55.75.

Metsera Stock Down 0.8%

Shares of MTSR stock opened at $51.70 on Wednesday. The stock has a 50 day simple moving average of $37.43 and a 200-day simple moving average of $30.78. Metsera has a 1-year low of $12.30 and a 1-year high of $54.47.

Metsera (NASDAQ:MTSR) last announced its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Trading of Metsera

Several large investors have recently added to or reduced their stakes in MTSR. Bank of New York Mellon Corp purchased a new stake in Metsera in the 1st quarter valued at $884,000. New York State Common Retirement Fund purchased a new stake in Metsera in the 1st quarter valued at $131,000. Alphabet Inc. purchased a new stake in Metsera in the 1st quarter valued at $135,059,000. Massachusetts Financial Services Co. MA purchased a new stake in Metsera in the 1st quarter valued at $13,111,000. Finally, Jennison Associates LLC purchased a new stake in Metsera in the 1st quarter valued at $9,679,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.